Chronic Myelogenous Leukemia (CML) - Cancer Science

What is Chronic Myelogenous Leukemia (CML)?

Chronic Myelogenous Leukemia (CML) is a type of cancer that originates in the bone marrow, where blood cells are produced. It specifically affects the white blood cells, causing an overproduction of immature cells known as myeloblasts.

What Causes CML?

CML is primarily caused by a genetic abnormality known as the Philadelphia chromosome. This abnormality results from a translocation between chromosomes 9 and 22, which creates an abnormal gene called BCR-ABL. This gene produces a protein that promotes the growth of leukemic cells.

What are the Symptoms of CML?

Symptoms of CML can vary but often include fatigue, unexplained weight loss, night sweats, and a feeling of fullness due to an enlarged spleen. Some patients may also experience bone pain and frequent infections.

How is CML Diagnosed?

Diagnosis of CML typically involves blood tests to check for elevated white blood cell counts and the presence of the Philadelphia chromosome. A bone marrow biopsy may also be performed to confirm the diagnosis.

What are the Treatment Options for CML?

Treatment for CML has advanced significantly with the development of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib. These drugs target the BCR-ABL protein and have dramatically improved outcomes for patients. In some cases, a bone marrow transplant may be considered.

What is the Prognosis for CML Patients?

The prognosis for CML patients has improved significantly with the advent of TKIs. Many patients can achieve long-term remission and have a near-normal life expectancy. However, the response to treatment can vary, and regular monitoring is essential.

What are the Challenges in Managing CML?

Challenges in managing CML include drug resistance, side effects of treatment, and the need for lifelong therapy. Regular follow-ups and molecular monitoring are crucial to ensure the effectiveness of the treatment and to manage any complications.

How Can Patients Cope with CML?

Coping with CML involves not just medical treatment but also emotional and psychological support. Patients are encouraged to join support groups, maintain a healthy lifestyle, and discuss any concerns with their healthcare providers. Emotional support from family and friends is also invaluable.

Relevant Publications

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.

Issue Release: 2024

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment.

Issue Release: 2024

SARS-CoV-2 and chronic myeloid leukemia: a systematic review.

Issue Release: 2024

AS1041, a novel derivative of marine natural compound Aspergiolide A, induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation.

Issue Release: 2024

Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro.

Issue Release: 2024

Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.

Issue Release: 2024

[The Effect and Safety of Flumatinib in Patients with Chronic Myelogenous Leukemia Failed First-and Second-line Treatment].

Issue Release: 2024

Leukemia in India: Insights Into Incidence, Prevalence, Mortality, and Disability-Adjusted Life Years.

Issue Release: 2024

Dasatinib-induced pleural effusions, pericardial effusion and pulmonary arterial hypertension: a case report.

Issue Release: 2024

Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater.

Issue Release: 2024

[Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia].

Issue Release: 2024

\"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells\".

Issue Release: 2024

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.

Issue Release: 2024

Imatinib-Induced Bone Marrow Aplasia in Chronic Myelogenous Leukemia.

Issue Release: 2024

Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection.

Issue Release: 2024

Acute Left Main Coronary Embolization Following Transcatheter Aortic Valve Implantation.

Issue Release: 2024

[Effect of Csn-B Combined with Imatinib on Apoptosis of Chronic Myeloid Leukemia Cells through Nur77/Pim-1/Drp1 Pathway].

Issue Release: 2024

[Advances in basic and clinical research of flumatinib].

Issue Release: 2024

Bosutinib: Pediatric First Approval.

Issue Release: 2023

Interleukin-9 production by type 2 innate lymphoid cells induces Paneth cell metaplasia and small intestinal remodeling.

Issue Release: 2023

How are Cancers of Internal Organs Diagnosed?

What Are the Long-Term Effects of Unaddressed Emotional Barriers?

How Does TIVA Compare to Inhalational Anesthesia?

What is Matching in Cancer Research?

What Public Policies Do Officials Advocate for to Reduce Cancer Rates?

Can Processed Foods Be Part of a Healthy Diet?

What is a Bone Marrow Transplant (BMT)?

How Do ATP Binding Site Inhibitors Work?

What Role Does Hydration Play in Cancer Nutrition?

What Are the Advantages of LHRH Antagonists Over Agonists?

Partnered Content Networks

Relevant Topics